Presentation is loading. Please wait.

Presentation is loading. Please wait.

Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic.

Published byLucas Max Ström Modified over 5 years ago

Similar presentations

Presentation on theme: "Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic."— Presentation transcript:

1 Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. AL, acute leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; NUT ca, NUT carcinoma; GLB, glioblastoma; GI, gastrointestinal; n, number of patients included; CR, complete remission; PR, partial remission; NR, no response. *This study included 70 patients at the time of reporting, and preliminary activity was reported in 10 patients with NUT carcinoma (67). Cited references: Berthon, et al. (60); Amorim, et al. (61); Stathis, et al. (64); Massard, et al. (65); Hottinger, et al. (69); Abramson, et al. (62); O'Dwyer, et al. (67); Shapiro, et al. (66); Postel-Vinay, et al. (70). Anastasios Stathis, and Francesco Bertoni Cancer Discov 2018;8:24-36 ©2018 by American Association for Cancer Research

Download ppt "Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic."

Similar presentations

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
LEUKEMIA & LYMPHOMA SOCIETY TEAM IN TRAINING. THE LEUKEMIA & LYMPHOMA SOCIETY WORLDS LARGEST VOLUNTARY HEALTH ORGANIZATION DEDICATED TO FUNDING BLOOD.

LEUKEMIA & LYMPHOMA SOCIETY TEAM IN TRAINING. THE LEUKEMIA & LYMPHOMA SOCIETY WORLDS LARGEST VOLUNTARY HEALTH ORGANIZATION DEDICATED TO FUNDING BLOOD.
Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.
Kochenderfer JN et al. Proc ASH 2013;Abstract 168.

Kochenderfer JN et al. Proc ASH 2013;Abstract 168.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
What is LDN? It is a lower dosage of the FDA-approved drug, naltrexone which is used to treat heroin and opium addiction by blocking the body’s opioid.

What is LDN? It is a lower dosage of the FDA-approved drug, naltrexone which is used to treat heroin and opium addiction by blocking the body’s opioid.
Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.
DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-

Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-
Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.

Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.
Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in 2008. There are 5400 cases of acute lymphoid leukemia (ALL),

Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in There are 5400 cases of acute lymphoid leukemia (ALL),
Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in 2008. There are 5400 cases of acute lymphoid leukemia (ALL),

Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in There are 5400 cases of acute lymphoid leukemia (ALL),
Relation of H pylori infection to upper GI tract conditions

Relation of H pylori infection to upper GI tract conditions
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Similar presentations

Ads by Google